Clinical Trials Browser

Phase 1/2 × Nasopharyngeal Neoplasms × spartalizumab × Clear all

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms